Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs

Cancers

CarinA. Uyl-de Groot¹  Brenda Leeneman¹  MargreetG. Franken¹  AlbertJ. ten Tije²  Gerard Vreugdenhil³  RozemarijnS. van Rijn⁴  Djura Piersma⁵  AlfonsJ. M. van den Eertwegh⁶  AstridA. M. van der Veldt⁷  Ellen Kapiteijn⁸  MaureenJ. B. Aarts⁹  JohnB. A. G. Haanen^1,10  KarinH. Herbschleb^1,11  JacobusJ. M. van der Hoeven^1,11  KarijnP. M. Suijkerbuijk^1,12  GekeA. P. Hospers^1,13  FranchetteW. P. J. van den Berkmortel^1,14  MichelW. J. M. Wouters^1,15  AlexanderC. J. van Akkooi^1,15  JanWillem B. de Groot^1,16 

[1] Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, 3062 PA Rotterdam, The Netherlands;Department of Internal Medicine, Amphia Hospital, Molengracht 21, 4818 CK Breda, The Netherlands;Department of Internal Medicine, Maxima MC, Dominee Theodor Fliednerstraat 1, 5631 BM Eindhoven, The Netherlands;Department of Internal Medicine, Medical Center Leeuwarden, Henri Dunantweg 2, 8934 AD Leeuwarden, The Netherlands;Department of Internal Medicine, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ Enschede, The Netherlands;Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1118, 1182 DB Amsterdam, The Netherlands;Department of Medical Oncology, Erasmus MC Cancer Institute, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands;Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands;Department of Medical Oncology, Maastricht University Medical Center+, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands;Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands;Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands;Department of Medical Oncology, UMC Utrecht Cancer Center, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands;Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands;Department of Medical Oncology, Zuyderland Medical Center, Dr. H. van der Hoffplein 1, 6162 BG Sittard-Geleen, The Netherlands;Department of Surgical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands;Oncology Center Isala, Isala, Dokter van Heesweg 2, 8025 AB Zwolle, The Netherlands;

关键词: metastatic melanoma;    healthcare costs;    real-world data;    immunotherapy;    targeted therapy;   

DOI  :  10.3390/cancers12041003

来源: DOAJ

【 摘 要 】

Immunotherapeutic and targeted drugs improved survival of patients with metastatic melanoma. There is, however, a lack of evidence regarding their healthcare costs in clinical practice. The aim of our study was to provide insight into real-world healthcare costs of patients with metastatic cutaneous melanoma. Data were obtained from the Dutch Melanoma Treatment Registry for patients who were registered between July 2012 and December 2018. Mean total/monthly costs per patient were reported for all patients, patients who did not receive systemic therapy, and patients who received systemic therapy. Furthermore, mean episode/monthly costs per line of therapy and drug were reported for patients who received systemic therapy. Mean total/monthly costs were € 89,240/€ 6809: € 7988/€ 2483 for patients who did not receive systemic therapy (n = 784) and € 105,078/€ 7652 for patients who received systemic therapy (n = 4022). Mean episode/monthly costs were the highest for nivolumab plus ipilimumab (€ 79,675/€ 16,976), ipilimumab monotherapy (€ 79,110/€ 17,252), and dabrafenib plus trametinib (€ 77,053/€ 12,015). Dacarbazine yielded the lowest mean episode/monthly costs (€ 6564/€ 2027). Our study showed that immunotherapeutic and targeted drugs had a large impact on real-world healthcare costs. As new drugs continue entering the treatment landscape for (metastatic) melanoma, it remains crucial to monitor whether the benefits of these drugs outweigh their costs.

【 授权许可】

Unknown